Cat. No.: HY-B0135S

Furosemide-d₅

Name: Furosemide-d5
Brand: MedChemExpress
SKU: HY-B0135S
Price: 500.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

Furosemide-d₅ is the deuterated-labeled Furosemide (HY-B0135). Furosemide is an orally active NKCC2 inhibitor that can cross the blood-brain barrier. Furosemide inhibits NKCC1, NKCC2, KCC2, KCC3, and KCC4. Furosemide selectively antagonizes GABA_A receptors containing α6 and β2/3 or β3γ2 subunits. Furosemide penetrates the blood-brain barrier and blocks renal tubular sodium-chloride reabsorption, increases urinary excretion of sodium, chloride, potassium, and calcium, and activates the renin-angiotensin-aldosterone system. Furosemide can be used in research on congestive heart failure, hypertension, and edema.

For research use only. We do not sell to patients.

Purity : 99.85%
CAS No.: 1189482-35-6
Formula: C₁₂H₆D₅ClN₂O₅S
Molecular Weight:335.77

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Furosemide-d₅ Chemical Structure

CAS No.: 1189482-35-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Application
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Cardiovascular Diseases

Application

1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

Chemical Information

CAS No. 1189482-35-6
Unlabeled CAS 54-31-9
Appearance Solid
Molecular Weight 335.77
Formula C₁₂H₆D₅ClN₂O₅S
Color White to off-white
SMILES

OC(C1=C(C=C(C(S(N)(=O)=O)=C1)Cl)NC([2H])([2H])C2=C([2H])C([2H])=C([2H])O2)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (297.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9782 mL

14.8911 mL

29.7823 mL

5 mM

0.5956 mL

2.9782 mL

5.9565 mL

10 mM

0.2978 mL

1.4891 mL

2.9782 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (295 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tucker BJ, et al. Effect of furosemide administration on glomerular and tubular dynamics in the rat. Kidney international. 1984 Aug;26(2):112-21.

[2]. Mitchell JR, et al. Hepatic necrosis caused by furosemide. Nature. 1974 Oct 11;251(5475):508-11.

[3]. Das PK, et al. Furosemide Stress Test and Renal Resistive Index for Prediction of Severity of Acute Kidney Injury in Sepsis. Cureus. 2023 Aug;15(8):e44408.

[4]. Kelly MR, et al. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther. 1974 Feb;15(2):178-86.

[5]. Inoue M, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney international. 1987 Aug;32(2):198-203.

[6]. McCurley JM, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. Journal of the American College of Cardiology. 2004 Sep 15;44(6):1301-7.

[7]. Korpi ER, et al. Furosemide interactions with brain GABAA receptors. British journal of pharmacology. 1997 Mar;120(5):741-8.

[8]. Cataliotti A, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004 Apr 06;109(13):1680-5.

[9]. Duchin KL, et al. Effect of furosemide on renal autoregulation. Kidney Int. 1977 Dec;12(6):379-86. [Content Brief]

[10]. Orlov SN, et al. NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension. Genes & diseases. 2015 Jun;2(2):186-196.

[11]. Limmer F, et al. Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration. The FEBS journal. 2015 Oct;282(19):3786-98.

[12]. Suki WN, et al. Acute treatment of hypercalcemia with furosemide. N Engl J Med. 1970;283(16):836-840.

[13]. Osmanovic E, et al. The Effect of Furosemide on Arterial Blood Pressure, Blood Glucose Levels and Incidence of Heart Arrhythmias. American Journal of Internal Medicine. 2017;5(3):41-45.

[14]. Tenzing D, et al. Effect of furosemide in the treatment of high-altitude pulmonary edema. BMC Pulm Med. 2024 Mar 4;24(1):109.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9782 mL	14.8911 mL	29.7823 mL	74.4557 mL
	5 mM	0.5956 mL	2.9782 mL	5.9565 mL	14.8911 mL
	10 mM	0.2978 mL	1.4891 mL	2.9782 mL	7.4456 mL
	15 mM	0.1985 mL	0.9927 mL	1.9855 mL	4.9637 mL
	20 mM	0.1489 mL	0.7446 mL	1.4891 mL	3.7228 mL
	25 mM	0.1191 mL	0.5956 mL	1.1913 mL	2.9782 mL
	30 mM	0.0993 mL	0.4964 mL	0.9927 mL	2.4819 mL
	40 mM	0.0745 mL	0.3723 mL	0.7446 mL	1.8614 mL
	50 mM	0.0596 mL	0.2978 mL	0.5956 mL	1.4891 mL
	60 mM	0.0496 mL	0.2482 mL	0.4964 mL	1.2409 mL
	80 mM	0.0372 mL	0.1861 mL	0.3723 mL	0.9307 mL
	100 mM	0.0298 mL	0.1489 mL	0.2978 mL	0.7446 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Furosemide-d₅